BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36512052)

  • 1. Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy.
    Maniar R; Wang PH; Washburn RS; Kratchmarov R; Coley SM; Saqi A; Pan SS; Hu J; Shu CA; Rizvi NA; Henick BS; Reiner SL
    Cancer Immunol Res; 2023 Feb; 11(2):164-170. PubMed ID: 36512052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD28/PD1 co-expression: dual impact on CD8
    Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
    J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human CXCR5
    Hofland T; Martens AWJ; van Bruggen JAC; de Boer R; Schetters S; Remmerswaal EBM; Bemelman FJ; Levin MD; Bins AD; Eldering E; Kater AP; Tonino SH
    Eur J Immunol; 2021 Mar; 51(3):703-713. PubMed ID: 33098668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of CD8
    Horton BL; Morgan DM; Momin N; Zagorulya M; Torres-Mejia E; Bhandarkar V; Wittrup KD; Love JC; Spranger S
    Sci Immunol; 2021 Oct; 6(64):eabi8800. PubMed ID: 34714687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutting Edge: Promoting T Cell Factor 1
    Wang PH; Washburn R; Maniar R; Mu M; Ringham O; Kratchmarov R; Henick BS; Reiner SL
    J Immunol; 2022 Aug; 209(4):660-664. PubMed ID: 35905999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor immunogenicity dictates reliance on TCF1 in CD8
    Escobar G; Tooley K; Oliveras JP; Huang L; Cheng H; Bookstaver ML; Edwards C; Froimchuk E; Xue C; Mangani D; Krishnan RK; Hazel N; Rutigliani C; Jewell CM; Biasco L; Anderson AC
    Cancer Cell; 2023 Sep; 41(9):1662-1679.e7. PubMed ID: 37625402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD45RA
    Kunert A; Basak EA; Hurkmans DP; Balcioglu HE; Klaver Y; van Brakel M; Oostvogels AAM; Lamers CHJ; Bins S; Koolen SLW; van der Veldt AAM; Sleijfer S; Mathijssen RHJ; Aerts JGJV; Debets R
    J Immunother Cancer; 2019 Jun; 7(1):149. PubMed ID: 31176366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8
    Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCF1
    Koh J; Kim S; Woo YD; Song SG; Yim J; Han B; Lim S; Ahn HK; Mun S; Kim JS; Keam B; Kim YA; Lee SH; Jeon YK; Chung DH
    Eur J Cancer; 2022 Oct; 174():10-20. PubMed ID: 35970031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive profile of TCF1
    Wang D; Fang J; Wen S; Li Q; Wang J; Yang L; Dai W; Lu H; Guo J; Shan Z; Xie W; Liu X; Wen L; Shen J; Wang A; Chen Q; Wang Z
    Int J Oral Sci; 2022 Feb; 14(1):8. PubMed ID: 35153298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer.
    Lau D; Khare S; Stein MM; Jain P; Gao Y; BenTaieb A; Rand TA; Salahudeen AA; Khan AA
    Nat Commun; 2022 Jul; 13(1):4053. PubMed ID: 35831288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in circulating PD-1
    Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
    Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade.
    Kang P; Liu D; Li L; Guo X; Ye Y; Li Y; Jiang Q; Lin S; Yuan Q
    Cytokine; 2023 Mar; 163():156133. PubMed ID: 36724715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.
    Cheung CCL; Seah YHJ; Fang J; Orpilla NHC; Lau MC; Lim CJ; Lim X; Lee JNLW; Lim JCT; Lim S; Cheng Q; Toh HC; Choo SP; Lee SY; Lee JJX; Liu J; Lim TKH; Tai D; Yeong J
    Front Immunol; 2023; 14():1150985. PubMed ID: 37342338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ectonucleotidase CD39 identifies tumor-reactive CD8
    Chow A; Uddin FZ; Liu M; Dobrin A; Nabet BY; Mangarin L; Lavin Y; Rizvi H; Tischfield SE; Quintanal-Villalonga A; Chan JM; Shah N; Allaj V; Manoj P; Mattar M; Meneses M; Landau R; Ward M; Kulick A; Kwong C; Wierzbicki M; Yavner J; Egger J; Chavan SS; Farillas A; Holland A; Sridhar H; Ciampricotti M; Hirschhorn D; Guan X; Richards AL; Heller G; Mansilla-Soto J; Sadelain M; Klebanoff CA; Hellmann MD; Sen T; de Stanchina E; Wolchok JD; Merghoub T; Rudin CM
    Immunity; 2023 Jan; 56(1):93-106.e6. PubMed ID: 36574773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.